SVB Wealth’s Bio-Rad Laboratories Class A BIO Stock Holding History

SVB Wealth’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-57	Closed	-$13.9K	–	645
2025 Q1	$13.9K	Buy	+57	New	+$17.1K	﹤0.01%	818

Other funds holding BIO

First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

VAM

Veritas Asset Management London, United Kingdom $5.56B AUM 3.46% 1-Year Est. Return

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

FPA

First Pacific Advisors El Segundo, California $8.09B AUM 21.95% 1-Year Est. Return

SVB Wealth's BIO Position: Q2 2025 in Review

SVB Wealth sold out of Bio-Rad Laboratories Class A (BIO) in Q2 2025, closing a stake of 57 shares — an estimated $13.9K sold.

SVB Wealth first reported a position in BIO in Q1 2025 and held it in 1 quarter. The position peaked at $13.9K in Q1 2025. 384 funds tracked by Wall St. Rank hold BIO as of Q2 2025.

SVB Wealth reported no remaining Bio-Rad Laboratories Class A position as of Q2 2025 after selling out during the quarter.
SVB Wealth sold 57 Bio-Rad Laboratories Class A shares in Q2 2025, an estimated $13.9K.
SVB Wealth first reported a position in Bio-Rad Laboratories Class A in Q1 2025 and held it in 1 quarter.
SVB Wealth's Bio-Rad Laboratories Class A position peaked at $13.9K in Q1 2025.
384 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2025.

Based on SVB Wealth's 13F filing for Q2 2025, filed 14 Aug 2025.